2024-04-23 18:30:19
One tool is a system for minimally invasive treatment of high-grade mitral (bicuspid) valve regurgitation. If left untreated, this condition can worsen the patient’s existing heart disease, lead to atrial fibrillation, pulmonary hypertension or even heart failure.
Mitral valve regurgitation is a life-threatening condition in which blood flows backward through the leaky bicuspid valve into the left atrium instead of the aorta during left ventricular contraction. This device is introduced into the heart through the femoral vein and implanted on the leaflets of the mitral valve, aligning them. Based on the anatomy of the patient’s mitral valve, the clamp is selected individually for each patient. In this way, a double valve is created, which reduces the backflow of blood and improves the blood pumping of the heart.
During the procedure, real-time imaging is applied – echocardiography and fluoroscopy. Real-time analysis of cardiac blood flow allows repositioning of the device until the leak is minimized. In addition, this system is designed to preserve future surgical options.
This system, which is centrally paid for by the Compulsory Health Insurance Fund (PSDF), is intended for cases where the patient’s mitral valve leak persists despite optimal medical and interventional treatment and when the patient cannot undergo conventional mitral valve surgery and the bicuspid valve anatomy is suitable for treatment by catheterization.
The procedure can only be performed in hospitals that have interventional cardiology departments with X-ray operating rooms. The decision to implant the system is made by a team of heart doctors, and only cardiologists and interventional cardiologists can perform the implantation.
Another important innovation, which will be purchased for medical facilities from July, is a left atrial atrial closure device with an introduction system.
This medical aid is intended for patients with non-valvular atrial fibrillation who cannot be treated with anticoagulants and for those patients who have no other alternative treatment for atrial fibrillation.
During the procedure, using real-time imaging, the delivery catheter of the system is inserted into the left atrium through the femoral vein, deployed in the appropriate position at the orifice of the atrial septum, and the implant is deployed. In this way, the left atrial septum is permanently sealed and the resulting thrombi are prevented from entering the patient’s systemic circulation, reducing the risk of life-threatening bleeding.
This one-time minimally invasive procedure reduces the patient’s risk of stroke for life. Studies show that the procedure improves the survival rate of patients with non-valvular atrial fibrillation who are at high risk of stroke. As a result, premature death and severe disability are reduced.
Implantation can only be performed by interventional cardiologists and electrophysiologists in the hospital.
The State Sick Fund under the Ministry of Health predicts that 1.5 million will be needed for centralized payment of new medical aid measures in the first half of the year. EUR PSDF funds.
2024-04-23 18:30:19